IL-ISACA
21.4.2021 15:37:06 CEST | Business Wire | Press release
Emerging technologies are essential to digital transformation and business progress—whether it is blockchain used in supply chains and in the financial industry or artificial intelligence in driving efficiency across sectors. IT professionals seeking to boost their skillset in emerging technologies and ensure their knowledge is up to date can now pursue the Certified in Emerging Technology (CET) certification from global IT professional association and learning organization ISACA.
Established IT professionals, students and recent grads alike can set themselves apart with employers and gain foundational knowledge about the Internet of Things (IoT), artificial intelligence (AI), blockchain and cloud without having prior experience. Along with the recently launched ISACA credential, the Information Technology Certified Associate (ITCA) , the CET certification is unique in offering a vendor-agnostic, hybrid learning model. The CET model features both performance-based and knowledge-based learning—including live labs in a virtual environment—and incorporates a stackable series of certificates.
These certificates, which can be achieved at one’s own pace from anywhere, provide both an examination of each technology and a holistic view of the connections among the emerging technologies, allowing IT professionals to upskill and cross-skill in the following domains:
- Cloud Fundamentals Certificate
- Blockchain Fundamentals Certificate
- IoT Fundamentals Certificate
- Artificial Intelligence Fundamentals Certificate
“It is important for professionals in IT audit, risk, security, governance and privacy to have an understanding of emerging technologies and how they intersect with their work, as well as impact their organizations at a business level,” says David Samuelson, ISACA CEO. “With the new Certified in Emerging Technology certification, ISACA is pleased to offer our global community the tools to gain this knowledge and skillset and continue to take their careers to new heights.”
The CET certification is a good fit for professionals at different levels and job functions—from students and recent graduates wanting to build their résumés, to those already established in roles in governance, risk and compliance; IT audit; network administration; software development; information security; enterprise architecture and business management who want to learn more about emerging technology and how it applies to their roles and organizations.
“Continual up-skilling is a strong signal of professionalism in all IT fields,” said Caitlin McGaw, Principal, Candor McGaw. “Hiring managers are actively looking for people with emerging technology skills. However, since companies are still ramping up these technologies, many professionals have not yet had the chance to gain that experience. Being able to demonstrate the accomplishment of high-quality training and hands-on work with emerging technology will be a substantial competitive advantage for experienced professionals and recent grads alike.”
The CET certification program offers study guides, self-paced training courses, virtual instructor-led training, additional lab packages and exams for each certificate, available at discounted rates to ISACA members. Custom training packages for up-skilling IT teams are also available. Once all four certificate exams are completed, the CET certification is awarded.
This new certification joins an established set of ISACA credentials that have been part of the professional community’s learning journey for years, including Certified Information Systems Auditor (CISA), Certified Information Security Manager (CISM), Certified in Risk and Information Systems Control (CRISC), Certified in the Governance of Enterprise IT (CGEIT), CSX Cybersecurity Practitioner Certification (CSX-P), Certified Data Privacy Solutions Engineer (CDPSE) and ITCA certification.
For more information about the CET certification, visit www.isaca.org/credentialing/cet . More detail about ISACA’s other credentials can be found at www.isaca.org/credentialing , and ISACA publications, audit programs and other resources on emerging tech, including the recently published blockchain framework, are available at www.isaca.org/resources/emerging-technology-resources .
About ISACA
For more than 50 years, ISACA® (www.isaca.org ) equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. ISACA is a global professional association and learning organization with more than 150,000 members who work in information security, governance, assurance, risk and privacy, and a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.
Twitter:
www.twitter.com/ISACANews
LinkedIn:
www.linkedin.com/company/isaca
Facebook:
www.facebook.com/ISACAGlobal
Instagram:
www.instagram.com/isacanews
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
